NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer

Active Not RecruitingN/A

Sponsor: Fudan University

Conditions: HR Positive/HER-2 Negative Breast Cancer

Countries: China

Luminal breast cancer is characterized by marked heterogeneity, resulting in diverse treatment responses and long-term outcomes. This project aims to integrate MRI and multiomics data to achieve non-invasive molecular typing and precise response prediction. By linking imaging phenotypes with underlying molecular and pathological characteristics, the investigators will develop predictive models for treatment resistance, recurrence, and metastasis, ultimately supporting personalized treatment strategies and precision oncology.

Eligibility overview

Sex: FEMALE

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Histopathologically confirmed invasive luminal breast cancer (HR+/HER2-);
2. Patients who underwent breast MRI examination.

Exclusion Criteria:

1. Pathological biopsy performed prior to the baseline MRI examination;
2. Patients have received any form of prior treatment for the breast cancer;
3. History of other malignancies;
4. Incomplete or poor-quality MRI and/or pathological images;
5. Missing clinical data.

Locations (1)

Shanghai, Shanghai Municipality, China